MASI Quote, Financials, Valuation and Earnings

iRhythm Technologies has a net margin of -45.89% compared to Masimo's net margin of -19.35%. Masimo's return on equity of -39.91% beat iRhythm Technologies's return on equity of -112.03%.

Masimo has a consensus price target of $184.37, signalling upside risk potential of 15.63%. On the other hand iRhythm Technologies has an analysts' consensus of $145.67 which suggests that it could grow by 6.33%. Given that Masimo has higher upside potential than iRhythm Technologies, analysts believe Masimo is more attractive than iRhythm Technologies.

Masimo has a beta of 1.187, which suggesting that the stock is 18.716% more volatile than S&P 500. In comparison iRhythm Technologies has a beta of 1.413, suggesting its more volatile than the S&P 500 by 41.267%.

Masimo has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. iRhythm Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Masimo pays -- of its earnings as a dividend. iRhythm Technologies pays out -- of its earnings as a dividend.

Masimo quarterly revenues are $372M, which are larger than iRhythm Technologies quarterly revenues of $158.7M. Masimo's net income of -$170.7M is lower than iRhythm Technologies's net income of -$30.7M. Notably, Masimo's price-to-earnings ratio is 116.80x while iRhythm Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Masimo is 4.38x versus 6.94x for iRhythm Technologies. Usually stocks with elevated PS ratios are considered overvalued.

LeMaitre Vascular has a net margin of -45.89% compared to Masimo's net margin of 18.39%. Masimo's return on equity of -39.91% beat LeMaitre Vascular's return on equity of 13.74%.

Masimo has a consensus price target of $184.37, signalling upside risk potential of 15.63%. On the other hand LeMaitre Vascular has an analysts' consensus of $104.50 which suggests that it could grow by 26.5%. Given that LeMaitre Vascular has higher upside potential than Masimo, analysts believe LeMaitre Vascular is more attractive than Masimo.

Masimo has a beta of 1.187, which suggesting that the stock is 18.716% more volatile than S&P 500. In comparison LeMaitre Vascular has a beta of 0.816, suggesting its less volatile than the S&P 500 by 18.388%.

Masimo has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. LeMaitre Vascular offers a yield of 0.87% to investors and pays a quarterly dividend of $0.20 per share. Masimo pays -- of its earnings as a dividend. LeMaitre Vascular pays out 32.65% of its earnings as a dividend. LeMaitre Vascular's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Masimo quarterly revenues are $372M, which are larger than LeMaitre Vascular quarterly revenues of $59.9M. Masimo's net income of -$170.7M is lower than LeMaitre Vascular's net income of $11M. Notably, Masimo's price-to-earnings ratio is 116.80x while LeMaitre Vascular's PE ratio is 41.72x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Masimo is 4.38x versus 8.34x for LeMaitre Vascular. Usually stocks with elevated PS ratios are considered overvalued.

Insulet has a net margin of -45.89% compared to Masimo's net margin of 6.22%. Masimo's return on equity of -39.91% beat Insulet's return on equity of 36.9%.

Masimo has a consensus price target of $184.37, signalling upside risk potential of 15.63%. On the other hand Insulet has an analysts' consensus of $336.85 which suggests that it could grow by 16.85%. Given that Insulet has higher upside potential than Masimo, analysts believe Insulet is more attractive than Masimo.

Masimo has a beta of 1.187, which suggesting that the stock is 18.716% more volatile than S&P 500. In comparison Insulet has a beta of 1.346, suggesting its more volatile than the S&P 500 by 34.619%.

Masimo has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insulet offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Masimo pays -- of its earnings as a dividend. Insulet pays out -- of its earnings as a dividend.

Masimo quarterly revenues are $372M, which are smaller than Insulet quarterly revenues of $569M. Masimo's net income of -$170.7M is lower than Insulet's net income of $35.4M. Notably, Masimo's price-to-earnings ratio is 116.80x while Insulet's PE ratio is 51.85x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Masimo is 4.38x versus 9.70x for Insulet. Usually stocks with elevated PS ratios are considered overvalued.

ResMed has a net margin of -45.89% compared to Masimo's net margin of 28.26%. Masimo's return on equity of -39.91% beat ResMed's return on equity of 25.76%.

Masimo has a consensus price target of $184.37, signalling upside risk potential of 15.63%. On the other hand ResMed has an analysts' consensus of $269.49 which suggests that it could grow by 5.99%. Given that Masimo has higher upside potential than ResMed, analysts believe Masimo is more attractive than ResMed.

Masimo has a beta of 1.187, which suggesting that the stock is 18.716% more volatile than S&P 500. In comparison ResMed has a beta of 0.774, suggesting its less volatile than the S&P 500 by 22.603%.

Masimo has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ResMed offers a yield of 0.83% to investors and pays a quarterly dividend of $0.53 per share. Masimo pays -- of its earnings as a dividend. ResMed pays out 27.65% of its earnings as a dividend. ResMed's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Masimo quarterly revenues are $372M, which are smaller than ResMed quarterly revenues of $1.3B. Masimo's net income of -$170.7M is lower than ResMed's net income of $365M. Notably, Masimo's price-to-earnings ratio is 116.80x while ResMed's PE ratio is 28.54x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Masimo is 4.38x versus 7.47x for ResMed. Usually stocks with elevated PS ratios are considered overvalued.